Tuesday 21 May, 2024 12:43 PM
Site map | Locate Us | Login
   Rainbow Medicare skid as Q4 PAT slides 5% YoY; ARPOB at Rs 54,185    GRP Ltd leads gainers in 'B' group    Rolex Rings Ltd leads gainers in 'A' group    ONGC records multi-fold jump in Q4 PAT to Rs 9,869 cr    Shriram Properties rises post signing JDA for prime land parcel in Bengaluru    Volumes jump at Aptus Value Housing Finance India Ltd counter    RVNL jumps after PAT climbs 33% to Rs 478 cr in Q4 FY24    IRFC gains as Q4 PAT jumps 34% YoY; board OKs fund raising upto Rs 50,000 cr    BEL hits life high as PAT jumps 30% YoY to Rs 1,797 cr in Q4 FY24    JSW Steel Q4 PAT drops 65% YoY to Rs 1,332 cr; declares dividend of Rs 7.30/ share    Oil India Q4 PAT rises 13% YoY; board OKs 1:2 bonus issue    Glenmark Pharma to commercialize BeiGene's oncology medicines in India    Energy shares gain    Capital Goods stocks edge higher    Metal shares gain 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Granules India gains after receiving US FDA nod for gout medicine
30-Apr-24   13:20 Hrs IST

The ANDA for Colchicine Capsules was filed by the company?s wholly owned foreign subsidiary Granules Pharmaceuticals, Inc. (GPI).

The approved drug is a bioequivalent and therapeutically equivalent to the reference listed drug (RLD) Mitigare Capsules of Hikma International Pharmaceuticals LLC (Hikma).

Colchicine Capsules are indicated for prophylaxis of gout flares in adults.

The current annual U.S. market for Colchicine Capsules is approximately $55 Million, according to MAT Feb 2024, IQVIA/IMS Health.

Granules now have a total of 64 ANDA approvals from the US FDA (63 Final approvals and 1 tentative approvals),? the company said in a statement.

Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs).

The pharma company's consolidated net profit rose 1.06% to Rs 125.65 crore on 0.82% increase in revenue from operations to Rs 1,155.58 crore in Q3 FY24 over Q3 FY23.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 32737684
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd